Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 131,856 Shares of Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the transaction, the executive vice president directly owned 146,403 shares in the company, valued at $1,745,123.76. The trade was a 47.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Nikita Shah also recently made the following trade(s):

• On Monday, August 25th, Nikita Shah sold 6,340 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.50, for a total transaction of $60,230.00.
• On Friday, August 22nd, Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock. The shares were sold at an average price of $9.66, for a total value of $1,105,992.72.

Amneal Pharmaceuticals Trading Up 1.0%

Shares of Amneal Pharmaceuticals stock traded up $0.12 during trading hours on Friday, reaching $11.64. 959,349 shares of the company’s stock were exchanged, compared to its average volume of 1,688,060. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $12.12. The company has a fifty day moving average of $10.33 and a 200-day moving average of $8.90. The firm has a market capitalization of $3.66 billion, a price-to-earnings ratio of 1,165.17 and a beta of 1.21.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%.The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Comerica Bank raised its stake in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the period. Headlands Technologies LLC acquired a new stake in Amneal Pharmaceuticals in the 1st quarter valued at $31,000. Exchange Traded Concepts LLC purchased a new position in Amneal Pharmaceuticals in the third quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. raised its position in Amneal Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company’s stock valued at $98,000 after purchasing an additional 1,735 shares during the period. Finally, Xponance Inc. lifted its stake in shares of Amneal Pharmaceuticals by 16.1% during the first quarter. Xponance Inc. now owns 13,183 shares of the company’s stock worth $110,000 after purchasing an additional 1,828 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AMRX. JPMorgan Chase & Co. increased their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.50.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.